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Nature MediciNe progression and recurrence 16 , and through single-cell RNA sequencing of bulk primary tumor specimens 17 . All of these analyses suggest the presence of multiple coexisting tumor subclones that may be important to the proliferative and invasive capacities of the tumor, as well as cell fate decisions in response to the tumor microenvironment and selective pressure associated with therapeutic intervention. The relative contributions to the tumorigenic phenotype of these subclones is unclear, as is to what extent they interact during the tumor's evolutionary history-key factors in understanding the implications for new treatment strategies 18 .
In adult GBM, multiple subclones may also be marked by differential, mutually exclusive gene amplification events present in an individual tumor [19] [20] [21] , an observation also reported in isolated specimens of DIPG 22, 23 . In these examples, cells harboring distinct receptor tyrosine kinase gene amplifications were found intermingled throughout tumor specimens in a manner that suggested an environment conducive to the coexistence of multiple cellular subpopulations [19] [20] [21] . Two-dimensional (2D) mapping of these subclones across specimens showed some evidence of a predilection of certain subclones for perivascular niches, invasive tumor fronts, or the periphery of necrotic areas 19, 20 . In evolutionary biology terms, this stable coexistence in conjunction with a degree of specialization appears to imply cooperativity 24 . This posits a selective advantage for an interactive cellular network and promotes biological diversity within a tumor population as an important driver of the malignant phenotype in these cancers.
With pGBM and DIPG harboring considerably fewer somatic mutations than adult GBM 13 , we sought to investigate the possibility of tumor heterogeneity reflecting cooperation of subclones in what we consider to be an ideal model system for cancers sharing these histologies. Through an integrated approach of single and multiple sequencing strategies of patient samples coupled with in vitro isolation of subclonal populations, we concluded that biological diversity is selected for across time and space, with genotypically and phenotypically distinct tumor compartments working together to enhance key tumorigenic features such as invasion and migration.
Results
pGBM and DIPG comprise multiple subclones. We reanalyzed whole-genome and exome sequencing from 142 recently published pGBM and DIPG specimens for which matched germline data were available [2] [3] [4] [5] [6] [7] . We calculated the cancer cell fractions (CCF) for all somatic single nucleotide variants (SNVs) and small insertions or deletions, taking into account the implied tumor cell percentage, overall ploidy, local copy number alterations and loss of heterozygosity 25, 26 (Supplementary Table 1 ). In almost all cases, we observed a complex inferred subclonal architecture suggestive not of a single clonal expansion, but of multiple codominant subclonal populations, regardless of tumor location (n = 93 DIPG, n = 20 other midline, n = 29 cerebral hemispheres) or histone mutation subgroup (n = 10 H3.3 G34R (H3F3A), n = 61 H3.3 K27M (H3F3A), n = 23 H3.1 K27M (HIST1H3B, HIST1H3C), n = 48 histone wild-type) ( Fig. 1a ). Despite this variability in the fraction of any tumor harboring a given mutation, at a gene level there were certain recurrent mutations that were found to be consistently clonal (H3F3A, HIST1H3B, HIST1H3C, ATRX, NF1), some that were found to be predominantly clonal, but with some subclonal examples (ACVR1, TP53), and some frequently found in subclonal populations (ATM, PIK3R1, PPM1D, PDGFRA, BRAF, PIK3CA) (Fig. 1b) . These data provide important evidence for the likely timing of these mutations during tumor evolution. Using the EXPANDS package 27, 28 , we used the sequencing data to predict an absolute number of subclones present in each tumor sample, deriving a median number of 6 (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , with more than 85% of tumors appearing to harbor 3-10 subclones ( Fig. 1c and Supplementary Table 2 ). The percentage of clonal alterations ranged from 100% (n = 1) to 5.2% (median = 35.0%) ( Supplementary Fig. 1a ). There was a direct relationship between the overall mutational burden (number of somatic coding SNVs) and number of subclones (Pearson r 2 = 0.2188, P = 4.36 × 10 −9 ), though with several outliers (Fig. 1d ). There were no differences in subclonal number between different anatomical sites ( Fig. 1e ), despite the differing survival times by tumor location 29 . pGBM with H3.3 G34R mutations had a significantly elevated number of subclones compared with other tumors (median = 8.5, P = 0.044, t-test), while there were significantly fewer in infants (< 3 years at diagnosis; median = 4, P = 0.0108) ( Fig. 1e ). Plotting the number of subclones against hazard ratios for overall survival in a similar manner to that described in a pan-cancer analysis 28 , we identified tumors harboring more than 10 subclones to have the worst prognosis (relative risk = 3.3) ( Supplementary Fig. 1b ). Fig. 1 | Pediatric GBM and DIPG harbor a complex subclonal architecture. a, Representative images (from n = 142) of six cases of pGBM and DIPG from different anatomical locations and with different histone H3 mutation status. For each case, a CIRCOS plot shows chromosomal ideograms on the outermost ring, with banding in black and gray and centromere in red, and highlights somatic SNVs and insertions or deletions on the next ring, DNA copy number changes (dark red, amplification; light red, gain; dark blue, homozygous deletion; light blue, single-copy loss) and loss of heterozygosity (yellow) on the inner rings, and intra-or interchromosomal translocations inside the circle (orange). The CCF for each somatic coding mutation is plotted as a histogram with a kernel density overplotted. In all cases, in addition to a peak of mutations present in 100% of cells (clonal), there is a complex pattern of subclonal mutations (< 95% CCF) forming peaks at low frequencies within a given tumor. b, Violin plot of CCFs for a given series of gene mutations across all 142 independent cases of pGBM and DIPG (H3.3 G34R or G34V, n = 10; H3.3 K27M, n = 61; H3.1 K27M, n = 23; ATRX, n = 22; NF1, n = 4; ACVR1, n = 27; TP53, n = ; ATM, n = 5; PIK3R1, n = 8; PPM1D, n = 11; PDGFRA, n = 7; BRAF, n = 5; PIK3CA, n = 15). The shaded area represents a CCF of 95-100% to indicate a clonal mutation. Purported drivers such as histone H3 mutations, ATRX and NF1 are almost wholly found to be clonal (though there are single outliers in some instances). Other genes such as PIK3CA, BRAF and PDGFRA are frequently found to be mutated in smaller subclonal compartments of the tumors. Kernel densities of CCFs are plotted for all samples harboring a given mutation (number of independent cases listed on figure) . c, The number of subclones present in 142 pGBM and DIPG is calculated from somatic mutation data using the EXPANDS package 27 and ordered first by the number of subclones (colored using a rainbow palette) and then by the proportion of the tumor defined by the main clone in each tumor. A single case was clonal, with more than 85% of cases harboring 3-10 subclones. d, Dot plot of the number of somatic coding SNVs (y axis) against the number of subclones (x axis), demonstrating a significant positive relationship (Pearson r 2 = 0.2188, P = 4.36 × 10 −9 , n = 142 independent samples). Horizontal bar, median. Individual tumors are colored by their histone H3 mutation status, with outliers often seen to harbor H3.3 G34R (blue). e, Clinical and molecular correlates of subclonal numbers. Box plots highlight lack of difference in the number of subclones on the basis of anatomical location, but an increased number in H3.3 G34R tumors (P = 0.044, t-test) and a reduced number in infants (< 3 years, P = 0.0108, t-test) across all n = 142 independent samples. The thick line within the box is the median, the lower and upper limits of the boxes represent the first and third quartiles, whiskers 1.5 times the interquartile range, and individual points outliers. Hemi, hemispheric. f, Prognostic implications. Kaplan-Meier curves demonstrate that H3.3 G34R tumors have a longer overall survival than other pGBM and DIPG (P = 3.94 × 10 −6 , log-rank test); however, despite the association of this subgroup with an increased number of tumor subclones, an elevated subclonal diversity shows a trend toward shorter survival across all pGBM and DIPG (P = 0.068, log-rank test). Comparisons included all n = 142 independent samples. *P < 0.05. **P < 0.01. Articles Nature MediciNe than 10 (P = 0.0082) were independent predictors of shorter survival ( Supplementary Fig. 1c ).
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The tumor cohort studied was heavily enriched in DIPG samples, and owing to the unresectability of these lesions, it comprised a mixture of pre-treatment biopsy samples and post-treatment autopsy samples 2,3,5-7 . We observed no systematic differences in subclonal architecture when comparing samples taken at these differing time points, regardless of diagnosis or histone mutation status ( Supplementary Fig. 1d ). We were able to assess this directly for eight cases for which paired pre-and post-treatment sequencing data were available. By plotting the change in major subclonal tumor proportion over time, we observed changes in the proportion of individual subpopulations in response to therapy and tumor evolution; in all cases, however, several significant populations remained unchanged, and both before and after treatment the tumor was inferred to harbor multiple subclones, suggesting either equivalent fitness of multiple subclones or pressures restricting the ability of any given clone to sweep to fixation ( Supplementary Fig. 1e ).
DIPG cells escape the pons early during tumor evolution.
More direct evidence for the presence of multiple, genetically distinct subclones could be seen from sequencing 62 topographically distinct samples from 14 different patients (Supplementary Table 3 ). Comparing the CCFs from across a given tumor sample clearly demonstrated both the ubiquitous presence of presumed driver alterations (histone mutations, NF1) ( Supplementary Fig. 2a ) but also a range of mutations private to only one portion of the tumor. Of note, each distinct tumor region itself was inferred to harbor multiple subclones.
The collection of DIPG samples at autopsy represented a unique opportunity to evaluate the spatial heterogeneity of these tumors. In one case (QCTB-R091/R092), distinct low-grade and high-grade components were manually dissected and found to harbor key oncogenic mutations in one and not the other region (for example, PIK3CA H1047R in grade IV and not grade II), in addition to ubiquitous drivers such as ACVR1 ( Supplementary Fig. 2b ). It has previously been shown that these diffusely infiltrating lesions may be found outside the pons and spread throughout the central nervous system at the time of death 30 . Multi-sample sequencing strategies allowed us to again identify early driver events present throughout the tumor cells of an individual patient (H3F3A, HIST1H3B), as well as those occurring only at the point of escape of cells from the brainstem, such as mutations in WNK2, known to act in glioma cell migration and invasion 31 ( Supplementary Fig. 2c ). Across multiple sites in multiple samples ( Fig. 2 , Supplementary Fig. 3 and Supplementary Table 3 ), mapping SNVs and copy number aberrations revealed branching evolutionary trajectories. This was particularly evident in the most extensively sampled cases ( Fig. 2) , where distinct branches highlighted the profound laterality of tumor evolution, while tumor cells found in midbrain, cerebellar and thalamic regions were seen to diverge early from the pontine mass. While the difference in mutational profiles may be a result of invasive cells cycling more slowly, the presence of convergent or parallel evolution in key oncogenic drivers such as PIK3CA, NF1, MKI67, NOTCH1 and DMNT3A ( Supplementary Fig.  3 ) strongly suggests a predominantly early evolutionary divergence of cells that subsequently migrated outside the pons.
In vitro isolation of genotypically and phenotypically distinct subclones.
To determine whether the subclonal tumor cell populations present in pGBM and DIPG represent functionally distinct entities (rather than simply reflecting stochastic alterations occurring as a result of increasing genetic instability), we devised a methodology to isolate and expand single tumor cells under stem cell conditions, referred to as 'stem-like' cells, in both 2D 32 and three-dimensional (3D) culture 33 for further analysis (Fig. 3a ). Using this approach, we identified three primary patient-derived H3.3 K27M mutant samples (two DIPG, one thalamic pGBM) ( Supplementary Fig. 4 ) from a well-characterized panel of six cultures ( Supplementary  Fig. 5a ,b) to readily form single-cell-derived colonies in both 2D and 3D, at rates varying between 7.5 and 20.8% of cells ( Fig. 3b ). Colonies isolated from SU-DIPG-VI were identified using highcontent image analysis ( Fig. 3c ,f) and displayed highly variable growth characteristics in vitro when grown as 3D neurospheres ( Fig. 3d ) and in 2D on laminin ( Fig. 3g ). When sequenced at high depth using a custom-designed targeted panel ( Supplementary  Table 4 ), in addition to ubiquitously shared mutations (for example, H3F3A, TP53), around half the colonies harbored a series of shared mutations not seen in the remainder (for example, PRSS1, CHD3), while most were also found to contain a series of private events restricted to individual cell populations, including genes associated with cell shape and motility (FLNC, CTTN, RANGAP1) ( Fig. 3e,h) . Individual laminin-grown colonies with fast (A-D10), intermediate (A-B8) and slow (A-E6) growth rates ( Fig. 3i ) were seen to have significantly differing capacities for invasion into Matrigel ( Fig. 3j ) and migration on fibronectin ( Fig. 3k ) in vitro. Thus, individual tumor samples contain a dynamic diversity of overlapping genotypic and phenotypic populations in the stem-like cell compartment.
Rare tumor subclones can harbor pathogenic variants driving differing phenotypes.
For HSJD-DIPG-007, we were able to utilize the ability to isolate these genetically and phenotypically distinct subclonal populations to investigate the role of individual genotypes without needing to artificially engineer the cells. We identified a single-cell-derived neurosphere colony (NS-F10) as harboring a private mutation in the histone H4 methyltransferase KMT5B (SUV420H1) ( Fig. 4a ), which was found to be present in the original bulk primary culture in only 2 of 678 reads (0.295%) ( Fig. 4b ). This mutation results in the acquisition of a stop codon at amino acid position 187 (R187*), predicted to truncate the protein.
Examining published sequencing datasets, we identified another case of pGBM from Schwartzentruber et al. 4 , PGBM18, as harboring a subclonal R699* truncating mutation of KMT5B in 12.2% of reads ( Fig. 4b ), demonstrating this is not a unique observation. By digital droplet PCR, we confirmed that this mutation was present in 49.77% (8,060 of 16,196) of droplets from NS-F10 (assuming heterozygosity, this reflects presence in 99.64% cells), present in 0.48% (108 of 22,512) of reactions from the original culture, and absent (not significantly different from normal human astrocyte control; 1 of 18,484, 0.009%) from a 'natural isogenic' (confirmed by exome sequencing) counterpart subclone NS-F8 ( Fig. 4c ). The KMT5B mutant (NS-F10) and wild-type (NS-F8) subclones did not show appreciable differences from each other, or from the heterogeneous original bulk HSJD-DIPG-007 cells, in terms of morphology or immunophenotype ( Supplementary Fig. 5c ). The methyltransferase encoded by the gene is involved predominantly in dimethylation and, to a lesser extent, trimethylation 34 of histone H4K20, and consequently by immunofluorescence we observed a reduction in H4K20me2 in NS-F10 compared to HSJD-DIPG-007 bulk cells and NS-F8 ( Fig. 4d ). An unbiased drug screen of all three colonies against 80 chemotherapeutic and targeted agents ( Supplementary Fig. 6a -c and Supplementary Table 5 ) revealed significantly enhanced sensitivity to multiple chemotypes of PARP inhibitors of the KMT5B mutant NS-F10 compared to wild-type NS-F8 and HSJD-DIPG-007 bulk cells (10-30 fold difference for talazoparib, 50% cell survival concentration (SF 50 ) 1 nM vs. 11 nM and 31 nM, respectively; 4.5-fold difference for olaparib, SF 50 0.85 μ M vs. 3.83 μ M and 3.80 μ M, NS-F10 vs. NS-F8 and HSJD-DIPG-007 bulk population ANOVA P < 0.001 in each case) ( Fig. 4e ). Notably, when subclones were cocultured, rather than a dilution effect dependent on the relative proportions, mixed cultures were as insensitive as the heterogeneous bulk population ( Supplementary Fig. 6d ). Thus the mutation appears to confer a loss of function on these cells, presumably due to an abrogated DNA repair process associated with Articles Nature MediciNe loss of H4K20me2 (but not H4K20me3 or total H4, Supplementary  Fig. 6e ) and recruitment of 53BP1 34 .
Distinct infiltrative phenotypes of genotypically divergent DIPG subclones in vivo.
RNA sequencing analysis of the subclones revealed elevated gene expression in NS-F10 cells of a range of genes associated with remodeling the extracellular matrix ( Fig. 4f and Supplementary Table 6 ). These included the fibronectin receptors α 3 -and α 5 -integrin, with differential protein expression validated by immunofluorescence and immunohistochemistry ( Fig. 4g) . Although there was a slightly enhanced growth capability of the heterogeneous HSJD-DIPG-007 bulk cells ( Fig. 4h ), NS-F10 and NS-F8 subclones were similar to each other in growth, though we did observe significant differences in invasion into Matrigel ( Fig. 4i ) and migration on fibronectin ( Fig. 4j ), even after growth had been controlled for. This absence of α -integrin expression likely underlies the inability of NS-F8 to migrate on fibronectin; of note, NS-F8 neurospheres also harbored a significantly reduced migratory capacity compared with NS-F10 on a range of other substrates, including tenascin-C, laminin and Matrigel ( Supplementary Fig. 6 f) . In all instances, the mixed population bulk HSJD-DIPG-007 cells were significantly more migratory than either subclone.
The KMT5B wild-type NS-F8 cells had significantly reduced invasive and migratory capacities, which could be reversed (unlike those of the KMT5B mutant NS-F10 cells) upon culture with conditioned medium from the HSJD-DIPG-007 bulk cells ( Fig. 4k ), suggesting the presence of expressed factors absent from the isolated NS-F8 cultures. These cells also differentially responded to the chemokine CXCL2 in terms of a significantly enhanced migration on fibronectin ( Fig. 4k ). We chose this CXC ligand because it was one of the most differentially expressed genes by RNA sequencing analysis in NS-F10 (and HSJD-DIPG-007 bulk) compared to NS-F8 ( Fig. 4f ). Thus we have a model whereby paracrine signaling between subclones underlies the cooperative interactions observed in mixed populations.
In line with in vitro data, phenotypic differences were also recapitulated in vivo, where both bulk cell populations and NS-F10 subclones formed diffusely infiltrating tumors within 23-24 weeks after orthotopic implantation in the pons of NOD-SCID mice, whereas NS-F8 lesions were substantially less infiltrative and conferred a lower tumor burden, even after 30-32 weeks, despite there being little difference in proliferative capacity and immunophenotype in the brains (Fig. 5a ). NS-F8 tumor-bearing mice also had a longer survival (median = 205 d (NS-F8) vs. 141.5 d (NS-F10) and 169 d (bulk), P = 0.0236, log-rank test) ( Fig. 5b) . Tumors from heterogeneous bulk cells were confirmed by digital droplet PCR to harbor a low subclonal frequency of KMT5B R187* mutation (0.23%) ( Fig. 5c ), showing no significant selective pressure against the heterogeneous population. Thus even rare tumor cell subclonal populations may have different behaviors in vitro and in vivo of importance to key phenotypic features of DIPG that currently preclude effective treatments.
Notably, we observed similar results in a second model. A slower growing subclone of SU-DIPG-VI in vitro, A-E6, formed a less cellular tumor ( Fig. 5d ) and had an extended survival when grown orthotopically in vivo of more than 118 d longer than a rapidly proliferating, highly invasive subclone (A-D10) and 154 d longer than the unselected bulk culture (P = 0.037, log-rank test) ( Fig. 5e ).
DIPG subclones cooperate to enhance tumorigenic phenotypes.
To explore the nature of these subclonal interactions, we differentially labeled and cocultured genotypically and phenotypically distinct subclones from two DIPG samples: A-E6 and A-D10 from SU-DIPG-VI ( Fig. 6a-d ) and NS-F8 and NS-F10 from HSJD-DIPG-007 ( Fig. 6e-h ). When cultured in equal proportions, having been replated as single neurospheres, although there was little difference in observed growth rates ( Fig. 6a,e ), there was a marked enhancement of invasion and migration conferred on the poorly motile subclones by coculture with their more invasive and migratory counterparts (Fig. 6b ,c,f,g). In both models, cell labeling allowed us to demonstrate that this was not a simple dilution effect of the mixture, but that the specific subclones otherwise lacking a pronounced ability to invade into Matrigel (Fig. 6d ) or migrate on fibronectin ( Fig. 6h ) had markedly enhanced phenotypes, clearly colocalized and moving in concert alongside their natural isogenic pairs (Supplementary Videos 1 and 2). In vivo, cocultured NS-F8 and NS-F10 were found to retain their mixed proportions and infiltrate more extensively throughout the central nervous system than NS-F8 alone ( Supplementary Fig. 6g ), conferring shorter survival on mice harboring these orthotopic tumors (P = 0.045, log-rank test) ( Supplementary Fig. 6h ). Thus we conclude that there exists an actively maintained cooperative network of subclones within DIPGs that depends on strongly positive interactions to elicit the highly aggressive clinical phenotypes seen in children with this incurable disease. 
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Discussion
Widespread intratumoral heterogeneity in human cancer has become a prevalent theme in high-throughput sequence analysis of tumor specimens, with critically important implications for the success of therapeutic targeting 35 . Less attention has been given to the functional implications of this subclonal diversity and the interactions between distinct tumor subpopulations. Here we utilize pGBM and DIPG as cancer types with a relatively low mutational burden, yet a high degree of heterogeneity, to isolate these genotypically and phenotypically different compartments and provide evidence that subclonal diversity is selected for as a result of cooperative interactions that promote tumorigenesis. Single-cell-derived colonies were established and expanded under stem cell culture conditions, though without marker preselection, in contrast to a recent approach 36 . Phenotypic differences were observed, in terms of morphology, growth, migration and invasion, that could be linked directly to concurrent genotypic differences in the subclones. These properties, first identified through high-content screening during initial expansion, were maintained upon repassaging in short-term culture, indicating inherently fixed characteristics in markedly different tumor cell subpopulations. SNVs differing among single-cellderived colonies could be found at low frequencies in the original tumor mass and thus were reflecting not an acquired artifact of the culture conditions but instead a propensity of genotypically distinct subclones to harbor stem-like properties, further evidenced through their tumorigenic capacity in vivo. It has previously been proposed that a branched Darwinian evolution model integrated with a hierarchy of multiple cancer stem cell populations may help explain the spatial and temporal characteristics of observed intratumoral heterogeneity 37 , with evidence provided in leukemia 38 and solid tumors [39] [40] [41] .
In our models, the differing phenotypes of individual subclones were substantially less prominent than in heterogeneous unsorted primary cultures, with enhanced growth, invasion and migration properties of mixed populations of cells supporting the interpretation of sequencing analyses suggesting that subclonal diversity is selected for spatially 42, 43 and temporally 44 in these tumors. The maintenance of such stable coexistence during tumor evolution implies a degree of cooperativity. In our example, we isolated 'natural isogenic' subclonal populations differing by a key loss-of-function mutation in an H4K20 methyltransferase, in which the more migratory mutant cells were able to confer such properties on their wild-type counterparts, seemingly at least in part through expression of key chemokines such as CXCL2. A similar concept of 'cooperative invasion' was first identified in melanoma 45 , whereby phenotypically distinct subpopulations of cells were found to comigrate, a phenomenon also observed in DIPG in our genotypically distinct cells. Likewise, a recent elegant paper making use of a lentivirally transduced triplenegative breast cancer cell line allowed reconstruction of an aggressive phenotype in vivo using only two cooperating subclones: those overexpressing IL-11 and VEGFD 46 . Such a mechanism obviates the need for clonal selection to drive tumorigenesis and predicts the maintenance of intratumoral heterogeneity we observe. Notably, the proportion of cells that harbor these more enhanced phenotypes may be low and may therefore remain unidentified in bulk tumor profiling studies, though remaining critical in tumor development and maintenance. pGBM harboring H3.3 G34R or G34V mutations were found to harbor a higher mutational burden and a greater subclonal diversity than other tumor subgroups. Although the mechanisms are not known, this likely reflects an underlying DNA repair defect associated with the inability of the mutant H3K36 to be trimethylated, disrupting its important function in mismatch repair 47, 48 . Despite wild-type (x axes) and R187* mutation (y axes) for normal human astrocytes, heterogeneous bulk cells, and subclones NS-F10 and NS-F8. Mutant reads are present in 49.77% of droplets from NS-F10, equating to 99.64% cells harboring a heterozygous mutation. They are absent from astrocytes and NS-F8, though are found in 0.48% of droplets from the original bulk preparation. Taken from n = 3 independent experiments. FAM and VIC denote the fluorescent dyes used. d, Heterogeneous bulk HSJD-DIPG-007 cells and subclones were stained using an antibody directed against H4K20me2 (green) or total H4 (red), with nuclei stained with DAPI (blue). Reduced expression of H4K20me2 is observed in KMT5B mutant NS-F10 cells. Representative images taken from n = 3 independent experiments. Scale bars, 50 µ m. e, Effect on cell viability (surviving fraction on y axes) of treatment of heterogeneous bulk cells and subclones with increasing concentrations of two different PARP inhibitors (x axes, log 10 scale). ANOVA was used to test for significance of NS-F10 vs. NS-F8 and HSJD-DIPG-007 bulk culture for talazoparib and olaparib. ***P < 0.001. Data derived from n = 3 independent experiments. f, RNA sequencing (RNA-seq). Heat map of gene expression analysis from RNA sequencing data highlighting differential expression in KMT5B mutant NS-F10 subclones compared to wild-type NS-F8. The most highly elevated genes included a range of extracellular matrix remodelers (represented in gene set enrichment analysis by the gene set "Bowie response to extracellular matrix") and numerous secreted chemokines (gene set "Reactome chemokine receptors bind chemokines"). KMT5B itself is also differentially expressed. All cell preparations were sequenced, n = 1, and statistical comparisons made by gene set enrichment analysis using the Kolmogorov-Smirnov test (P) with multiple correction testing using the false discovery rate (q). ES, enrichment score. g, Left: immunofluorescence of bulk HSJD-DIPG-007 cells and subclones stained using an antibody directed against α 5 -integrin (red). Nuclei are stained with DAPI (blue). Right: immunohistochemistry of embedded bulk HSJD-DIPG-007 cells and subclones stained using an antibody directed against 
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Nature MediciNe this, these tumors do not have the mutational burden of hypermutator cases with biallelic mismatch repair deficiency, for whom immune checkpoint inhibitors appear to offer an exciting new therapeutic option 49 . It is not clear, therefore, that patients with H3.3 G34R or G34V mutations would benefit from a similar strategy. Unfortunately, no H3.3 G34R or G34V cultures were available for our study, and most of our functional work was focused on H3.3 K27M mutant DIPG samples, which were more amenable to single-cell-derived colony formation in our assay than other tumor genotypes (although it is not clear whether this reflects imperfect culture conditions for these subgroups). It has previously been shown that these diffusely infiltrating lesions may be found outside the pons and spread throughout the central nervous system at the time of death 30 . Reconstructing phylogenies through sequencing of tumor cells spread throughout the brain at autopsy indicates an early escape of migratory cells from the pons, a Targeted sequencing before the rapid proliferative expansion occurring by the time of presentation and treatment. This has important implications for locally delivered therapies and reopens the debate concerning the initial use of whole-brain irradiation in children with DIPG. The later acquisition of convergent mutations in genes controlling key signaling pathways associated with proliferation at these distant sites also underlies the challenges in preventing tumor recurrence and/or metastasis at anatomically distinct sites in the central nervous system 50 .
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In summary, these data demonstrate that pGBM and DIPG harbor a complex admixture of genotypically and phenotypically distinct stem-like cells driving a functionally based intratumoral Week 10
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Fig. 5 | Distinct infiltrative phenotypes of genotypically divergent DIPG subclones in vivo. a, Heterogeneous HSJD-DIPG-007 bulk cells and NS-F10
and NS-F8 subclones were implanted directly into the pons of NOD-SCID mice and tumors allowed to form over 8 months. At weeks 23-24, bulk cells and NS-F10 formed diffusely infiltrating tumors throughout the brain, as seen by H&E staining as well as immunohistochemistry with anti-human nuclear antigen (HNA) or astrocyte marker GFAP, whereas NS-F8 had formed considerably less infiltrative lesions even at 30 weeks. Representative images from a total of n = 4 mice per group. Main scale bars, 1,000 µ m; inset scale bars, 50 µ m. b, Tumor-bearing animals implanted with NS-F8 subclones had significantly longer survival than heterogeneous HSJD-DIPG-007 bulk cells and NS-F10 (P = 0.0236, log-rank test, n = 4 mice per group). *P < 0.05. c, Digital droplet PCR. Plot of assay for KMT5B wild-type (x axes) and R187* mutation (y axes) for normal human astrocytes and tumors from mice implanted with heterogeneous bulk cells, and subclones NS-F10 and NS-F8. Mutant reads are present in 51.33% droplets from NS-F10 and 0.23% droplets from the original bulk preparation. Taken from n = 3 independent experiments. d, Heterogeneous SU-DIPG-VI bulk cells and A-D10 and A-E6 subclones were implanted directly into the pons of nude mice and tumors allowed to form over 8 months. At week 10, bulk cells and A-D10 formed highly cellular, infiltrating tumors, as seen by H&E staining or immunohistochemistry with anti-HNA, whereas A-E6 had formed considerably less cellular lesions even at 14 weeks. Representative images from a total of n = 8 mice per group. Main scale bars, 1,000 µ m; inset scale bars, 50 µ m. e, Tumorbearing animals implanted with A-E6 subclones had significantly longer survival than heterogeneous SU-DIPG-VI bulk cells and A-D10 (P = 0.037, logrank test, n = 8 mice per group).
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heterogeneity. Understanding how the derived subclones interact and adapt to the tumor microenvironment, and to therapy, will be a key requirement for maximizing patient benefit from existing treatment options. Future strategies aimed at disrupting these interactions may represent a new therapeutic approach in these diseases.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0086-7. Immunofluorescence. pGBM and DIPG cells were grown either adherent on laminin-precoated 8-well chamber slides (Cole Palmer) or in suspension as neurospheres in 75 cm 2 tissue culture flasks. Cells on chamber slides were fixed with 4% paraformaldehyde at room temperature for 10 min and washed three times with phosphate-buffered saline (PBS) solution. Neurospheres were collected into conical tubes, centrifuged for 10 min at 146g, washed once with PBS and, after a further centrifugation, fixed in 4% paraformaldehyde overnight 4 °C and then embedded into agarose as previously described 53 . Paraffin-embedded neurospheres were sectioned using a microtome at 4 µ m thickness. Cells were permeabilized with 0.5% Triton X-100 solution for 10 min at room temperature and then blocked with appropriate serum according to the species of secondary antibody for 1 h at room temperature. Secondary antibodies used were goat anti-mouse (A11001, ThermoFisher), donkey anti-rabbit (A31572, ThermoFisher) and goat anti-rabbit (A11008, ThermoFisher (50:50) , and allowed to form a single neurosphere per well (n = 6). One or 2 d after seeding, migration assays were performed on fibronectin-(NS-F10 and NS-F8) or Matrigel-(D10 and E6) coated 96-well flat-bottom plates (Essen Bioscience), and brightfield and fluorescent images were acquired on an IncuCyte ZOOM (Essen Bioscience). Images of a region of interest of identical size across all replicates (n = 6) were imported into ImageJ software and the number of cells migrated (at 12 h for D10 and E6 and 48 h for NS-F10 and NS-F8) was manually counted using the cell counter plugin and normalized to the cell ratio (100% for the monocultures and 50% for the cocultures). Growth was assessed using the Celigo S as above, while invasion was measured as area covered using ImageJ upon image calibration using a 1-mm graticule. Time lapse videos were also acquired using a Zeiss LSM700 confocal microscope with images acquired every 30 min.
In vivo orthotopic xenograft. All experiments were performed after review by the Animal Welfare and Ethical Review Board at Institute of Cancer Research, in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986, the United Kingdom National Cancer Research Institute guidelines for the welfare of animals in cancer research and the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines. A single-cell suspension from heterogeneous bulk cells or subclones (HSJD-DIPG-007, NS-F10, NS-F8 or coculture, in Matrigel; SU-DPG-VI, A-D10 and A-E6, in medium) was prepared immediately before implantation in four to eight NOD-SCID (HSJD-DIPG-007 and subclones) or nude (NCr-Foxn1 nu ) mice (SU-DIPG-VI and subclones) randomly allocated per group at P35. Animals were anesthetized with ketamine and xylazine (100 mg/ kg and 5 mg/kg) and maintained under 1% isoflurane. The cranium was exposed via midline incision under aseptic conditions and 1 × 1 mm deep hole was drilled through the skull to the dura. Mice were placed in a stereotactic apparatus and 200,000 cells in 5 μ L were stereotactically implanted in the pontine area using a digital pump at an infusion rate of 2 μ L/min and a 31-gauge Hamilton syringe. Coordinates used were 1.0 mm lateral to midline, 0.8 mm posterior to lambda, and -4 mm deep to cranial surface. At the completion of infusion, the syringe needle was allowed to remain in place for a minimum of 2 min, then slowly manually withdrawn to minimize backflow of the injected cell suspension. Mice were followed for up to 8 months and were sacrificed upon deterioration of condition and tissue taken for further analysis. Mouse brains were collected and fixed in 10% buffered formalin solution for 48 h before division into four parts and embedding in paraffin. Sections 4 µ m thick were cut and stained with hematoxylin and eosin. For immunohistochemistry, sodium citrate (pH 6.0) heat-mediated antigen retrieval was performed and staining was carried out using antibodies directed against human nuclear antigen (HNA) (MAB 4383, Millipore, 1:100), human GFAP (M0761 clone 6F2, Dako, 1:300), H3K27me3 (9733, Cell Signaling, 1:100)
Once the Matrigel solidified, 100 μ L per well of culture medium was added on top. Starting from time zero, and at intervals up to 72 h, automated image analysis was carried out on a Celigo S imaging cytometer using the Confluence application. The degree of cell spreading in the Matrigel was measured and the data plotted either as percentage of total area in the field of view covered by invading cells or as percentage of initial size of each neurosphere at time zero (n = 3). 3D migration assays were similarly performed as previously described 53, 55 , with some modifications. Briefly, flat-bottomed 96-well plates (Greiner Bio-one) were coated for 2 h at room temperature with 50 μ L per well of fibronectin, laminin, tenascin (Sigma-Aldrich) 10 μ g/mL in PBS with calcium and magnesium, or 125 μ g/mL Matrigel (Corning) in culture medium in absence of growth factors. Once coating was completed, a total of 200 µ L per well of culture medium was added. For stimulation assays, CCL2, CXCL2 (20 ng/mL and 50 ng/mL in TSM medium starved of all growth factors and B27 supplement) or medium harvested after 5 d culture of heterogeneous HSGD-DIPG-007 cells were used. A total of 100 μ L medium was removed from ULA 96-well round-bottomed plates containing neurospheres 250-300 μ m in diameter, and the remaining medium including the neurosphere were transferred to the precoated plates. Starting from time zero, and at intervals up to 72 h, automated image analysis was carried out on a Celigo S cytometer using the Confluence application. The degree of cell spreading on the different matrices was measured and data plotted either as percentage of total area in the well covered by migrating cells or as a percentage of the initial size of each neurosphere at time zero (n = 3). A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data collection
For acquisition of quantitative in vitro cell culture data, the Confluence (2D) and Tumorsphere (3D) applications on the Celigo S imaging cytometer (Nexcelom Inc) were used. The QuantaSoft program (v1.4) aligned to the QX200 digital PCR platform (Bio-Rad) fitted the droplet counts to the Poisson distribution in order to enumerate the DNA copies, from which the DNA concentration and mutant fraction could be calculated.
Data analysis
Custom scripts for data handling are available upon request. For both published and newly generated raw sequencing data, reads were aligned to the hg19 build of the human genome using bwa v0.7.5a (bio-bwa.sourceforge.net), and PCR duplicates removed with PicardTools 1.5 (pcard.sourceforge.net). Somatic single nucleotide variants were called using the Genome Analysis Tool Kit v3.3-0 based upon current Best Practices using local re-alignment around InDels, downsampling and base recalibration with variants called by the Unified Genotyper (www.broadinstitute.org/gatk/). Structural variants were called from whole genome data using Breakdancer (http:// breakdancer.sourceforge.net) filtered to remove commonly multimapped regions to identify somatic breakpoints separated by a minimum of 10kbp involving at least one Ensembl gene. Variants were annotated using the Ensembl Variant Effect Predictor v71 (www.ensembl.org/info/docs/variation/vep) incorporating SIFT (sift.jcvi.org) and PolyPhen (genetics.bwh.harvard.edu/pph2) predictions, COSMIC v64 (www.sanger.ac.uk/genetics/CGP/cosmic/) and dbSNP build 137 (www.ncbi.nlm.nih.gov/sites/SNP) annotations. Copy number was obtained by calculating log2 ratios of tumour/normal coverage binned into exons of known genes, smoothed using circular binary segmentation (www.bioconductor.org). Cancer cell fractions were calculated from somatic allele-specific copy number profiles derived by ASCAT (https://github.com/Crick-CancerGenomics/ascat). Intratumoral heterogeneity and the number and frequency of subpopulations within individual tumour samples were calculated with the EXPANDS algorithm (http://dna-discovery.stanford.edu/software/ nature research | reporting summary April 2018 expands/). Distance matrices derived from the cancer cell fractions of non-synonymous somatic coding mutations in each sample were used to construct phylogenies based upon neighbour-joining algorithms utilising the nested subpopulation calculated as part of EXPANDS, and visualized using the ape package (v3.1-4) in R. RNA sequences were aligned to hg19 and organised into de-novo spliced alignments using bowtie2 and TopHat2 (https://ccb.jhu.edu/software/tophat). Raw read counts and fragments per kilobase per million reads mapped (FPKPM) were calculated for all known Ensembl genes in assembly v74 using bedtools (http://bedtools.readthedocs.org) and Cufflinks (http://cole-trapnell-lab.github.io/cufflinks/).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
All data are publicly available in EGA under accession number EGAS00001001436.
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Sample size
For the genomic analyses, 142 pGBM and DIPG patients for whom matched germline data was available represented the sum total of publicly available data at the time. For the in vivo experiment, sample size was in part determined pragmatically as the mazimum number that could be implanted in one day across all cell preparations to be tested, and was powered to detect a 20% difference in survival at an alpha of 0.05 and a power of 0.75
Data exclusions There were no data exclusions.
Replication
All in vitro experiments were carried out independently in triplicate.
Randomization For the in vivo experiment, mice were randomly allocated to each individual cell preparation for implantation. 
Blinding
